”Investors are much more cynical today”
What are the lessons learned from the many Danish biotech companies that have been forced to call it quits, and what have the ups and downs of the noughts meant for the investor environment in Denmark? Medwatch is looking for the answers in a new miniseries.
by Benjamin Werner Christensen
As described in part one of the series “When the ships left the port”, the many Danish biotech companies founded between 2000 and 2004 have developed in very different directions. One of the main conclusions was that a lot of companies – probably too many – had seen the light of day during those years. The question is what lessons have been learned and how the future success of Danish biotech can be ensured. There are already indications that several of the newer companies can be expected to perform better, collectively speaking, than the approximately 70 companies founded in the early 2000s.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Has Danish biotech been a success?
For abonnenter
